Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis $(IPF.UK)$. The trial achieved its primary endpoint, showing statistically significant reductions in 24-hour cough frequency across all dose groups, including 108 mg BID and 54 mg BID (p <0.0001) and 27 mg BID (p<0.01), with a 43.3% placebo-adjusted change at the highest dose. Rapid reductions were noted as early as Week 2. Haduvio was generally well-tolerated, with discontinuation rates due to adverse events similar to those in the placebo group. Trevi plans to request an End-of-Phase 2 meeting with the FDA later in the year and intends to initiate a Phase 3 program in the first half of 2026. A conference call and webcast to discuss these results will be held today at 8:30 a.m. ET.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.